Sex hormone-binding globulin (SHBG) is a hepatic glycoprotein that binds testosterone and estradiol with high affinity, controlling the bioavailable (unbound) fraction of these hormones in circulation. Beyond hormone transport, SHBG is a sensitive marker of hepatic insulin signaling — low SHBG is tightly linked to insulin resistance, hepatic steatosis, and type 2 diabetes risk, making it valuable for both hormonal and metabolic assessment.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you're tracking reproductive hormones, metabolic health, or investigating insulin resistance and diabetes risk, SHBG matters. SHBG reveals how much of your testosterone and estradiol is actually free and active in tissue — not just total levels. Even if testosterone looks “normal,” low SHBG means more is bound and less is bioavailable, shifting functional hormone status.
SHBG also flags hepatic metabolic dysfunction. Low SHBG is one of the strongest pre-clinical predictors of type 2 diabetes in men, independent of body weight, and clusters tightly with insulin resistance, fatty liver, and metabolic syndrome. If you're concerned about metabolic health, energy, or long-term disease prevention, SHBG deserves testing alongside glucose, insulin, HbA1c, and triglycerides.
In Swedish healthcare, SHBG is not always ordered on standard vårdcentral screening but is commonly added when testosterone testing is requested or when metabolic investigation is warranted. Private longevity panels include it as standard.
Measures hormone bioavailability directly. SHBG quantifies binding capacity, so you know how much free testosterone and estradiol are available to tissues, not just total hormone levels.
Flags insulin resistance and metabolic dysfunction early. Low SHBG often precedes diabetes diagnosis and is tightly associated with hepatic steatosis and metabolic syndrome, even in people with normal BMI.
Predicts type 2 diabetes risk independently. In epidemiological studies, low SHBG in men is one of the strongest pre-clinical markers of future diabetes risk, more predictive than age, BMI, or fasting glucose alone.
Contextualizes reproductive health assessment. When paired with testosterone or estradiol, SHBG helps distinguish between low total hormone and hormonal imbalance due to high binding.
Tracks metabolic intervention response. SHBG rises with improved insulin sensitivity, weight loss, and exercise, making it a useful marker of underlying metabolic recovery.
Identifies hepatic metabolic stress. SHBG declines with hepatic insulin resistance and fatty liver disease, serving as a sensitive hepatic metabolic marker independent of standard liver enzymes.
Structure and transport role. SHBG is a 373-amino-acid glycoprotein produced by the liver. It binds testosterone and estradiol with extremely high affinity — much higher than albumin, the other major carrier protein. In healthy individuals, roughly 97–99% of circulating testosterone is protein-bound; SHBG carries about 66% and albumin the rest. Only the remaining free testosterone (1–3%) can cross cell membranes and activate androgen receptors. SHBG effectively sets the ceiling on hormone bioavailability.
The insulin-sensing link. SHBG synthesis is exquisitely sensitive to hepatic insulin signaling. Hyperinsulinemia and hepatic insulin resistance suppress SHBG production — the liver makes less protein. This is not random: when the liver senses chronic elevated insulin (as in metabolic syndrome), it downregulates SHBG as part of a broader metabolic dysregulation. Conversely, improved insulin sensitivity and weight loss upregulate SHBG. This makes SHBG a barometer of hepatic metabolic health, independent of circulating glucose.
Why this matters for longevity. The association between low SHBG and type 2 diabetes risk is causal in mechanism: SHBG decline reflects hepatic insulin resistance, which drives both hepatic lipogenesis (fatty liver) and beta-cell stress (eventual diabetes). Low SHBG is not merely a symptom of metabolic disease — it reflects the underlying hepatic dysfunction that precedes clinical disease. In this sense, SHBG is a window into the earliest stages of metabolic deterioration.
Identifies hidden insulin resistance. Many people with insulin resistance and early hepatic steatosis have normal fasting glucose and HbA1c. SHBG captures this metabolic stress earlier, especially in lean individuals where standard metabolic markers lag.
Reveals sex-hormone imbalance masked by total levels. High total testosterone with low SHBG means most is bound — bioavailable hormone is actually low. Standard hormone panels miss this discordance without SHBG.
Predicts diabetes progression independent of weight. In epidemiology, low SHBG predicts future diabetes in lean men as powerfully as in obese men, showing that hepatic metabolic dysfunction can occur without obesity and is captured by SHBG before glucose rises.
Contextualizes reproductive aging and hormonal intervention. In midlife men and women, SHBG rises with age. Understanding your absolute SHBG level and trajectory clarifies whether hormone supplementation (if considered) will be physiologically appropriate and how interventions affect circulating hormone bioavailability.
Standard Swedish reference (vårdcentralen): Men 15–55 nmol/L; women 30–120 nmol/L (age and menstrual cycle-dependent). These ranges are broad and represent population-level “normal” but do not distinguish metabolic risk.
Loovi optimal (longevity): Men >30 nmol/L; women >60 nmol/L. At these levels, hepatic insulin signaling is generally robust and diabetes risk is lower. Below these thresholds, insulin resistance signals intensify.
Metabolic caution zone: Men <20 nmol/L; women <40 nmol/L. This range suggests hepatic insulin resistance and significantly elevated type 2 diabetes risk, even in lean individuals. Concurrent HbA1c, fasting insulin, and liver imaging (ultrasound or FIB-4 score) are warranted.
SHBG typically rises gradually with age in both sexes, peaks around age 70, then may stabilize or decline slightly. Women's SHBG varies across the menstrual cycle (higher in follicular phase) and increases substantially with estrogen exposure (oral contraceptives, HRT, pregnancy). A single SHBG in the low-normal range during these conditions may still warrant investigation if accompanied by metabolic complaints or other insulin-resistance markers.
Low SHBG (<20 nmol/L in men, <40 nmol/L in women). This indicates hepatic insulin resistance and metabolic stress. The liver is not responding normally to insulin, suppressing SHBG production as a consequence. Low SHBG clusters with elevated fasting insulin, high triglycerides, low HDL, elevated HbA1c or impaired fasting glucose, fatty liver (on ultrasound), and increased visceral adiposity. Even in lean individuals, low SHBG with elevated fasting insulin or HbA1c signals future diabetes risk. In reproductive contexts, low SHBG means a larger fraction of testosterone is bioavailable, which can exacerbate PCOS symptoms in women or shift hormonal balance in men.
Optimal SHBG (men >30 nmol/L, women >60 nmol/L). This reflects intact hepatic insulin sensitivity and metabolic health. The liver is producing adequate SHBG, indicating the insulin signaling pathway is functional. Optimal SHBG typically correlates with better glucose tolerance, lower visceral fat, healthier lipid profiles, and lower type 2 diabetes risk. In reproductive contexts, hormone bioavailability is stable and physiologically appropriate.
Very high SHBG (>70 nmol/L in men, >150 nmol/L in women). Elevated SHBG can indicate hyperthyroidism, estrogen excess (oral contraceptives, HRT, pregnancy, liver disease), aging, or use of certain anticonvulsants. Paradoxically, very high SHBG reduces bioavailable hormone and can present as low libido, fatigue, or reduced fertility if accompanied by low total testosterone or estradiol. Thyroid function, liver function, and reproductive hormone status should be checked.
Factors that influence SHBG. Pregnancy and oral contraceptive use elevate SHBG substantially (by up to 4–5 fold). Menstrual cycle phase shifts SHBG (higher in follicular phase). Hyperthyroidism and thyroid replacement therapy can raise SHBG; hypothyroidism lowers it. Acute illness, intense exercise within 48 hours, and severe caloric restriction can transiently suppress SHBG. Certain anticonvulsants (phenytoin) and corticosteroids alter SHBG. Hepatitis and severe liver disease suppress SHBG despite liver dysfunction. These factors should be considered when interpreting a single SHBG measurement.
Insulin resistance and metabolic syndrome. Hepatic insulin resistance suppresses SHBG synthesis. SHBG declines as insulin levels rise, and this relationship is tighter than the relationship between SHBG and glucose. Obesity, visceral adiposity, and sedentary lifestyle all drive this pattern, but lean insulin-resistant individuals also show suppressed SHBG.
Polycystic ovary syndrome (PCOS) and androgen excess. In PCOS, elevated androgens (likely from theca cell hyperresponsiveness to LH) suppress SHBG further, creating a vicious cycle of rising free androgens and falling SHBG. SHBG decline also reflects underlying hepatic insulin resistance common in PCOS.
Thyroid dysfunction. Hyperthyroidism raises SHBG; hypothyroidism lowers it. TSH and free T4 should be checked if SHBG is out of range, especially if other metabolic markers are discordant.
Estrogen and androgen exposure. Exogenous estrogen (oral contraceptives, HRT, pregnancy) raises SHBG. Androgens and androgen replacement therapy suppress SHBG. Aging naturally raises SHBG in both sexes due to declining androgens and shifting hormonal profiles.
Hepatic dysfunction and liver disease. Hepatitis, cirrhosis, and fatty liver disease suppress SHBG, reflecting loss of synthetic capacity. Paradoxically, severe liver disease reduces SHBG despite obvious hepatic pathology, making SHBG less useful as a marker in established cirrhosis.
Improve hepatic insulin sensitivity through weight loss and exercise. Sustained caloric deficit, especially with retained lean mass (resistance training), lowers fasting insulin and upregulates SHBG. Even modest weight loss (5–10% of body weight) improves hepatic insulin signaling and raises SHBG. Regular aerobic and resistance exercise improves whole-body insulin sensitivity, particularly in skeletal muscle and liver.
Reduce refined carbohydrates and fructose. Dietary fructose drives hepatic lipogenesis and hepatic insulin resistance. Reducing sugar-sweetened beverages and refined grains improves hepatic metabolic health and SHBG. The mechanism involves reduced hepatic triglyceride accumulation and improved insulin receptor signaling in hepatocytes.
Support liver health through alcohol moderation and micronutrient sufficiency. Chronic alcohol suppresses SHBG and drives hepatic steatosis. Moderation is protective. Adequate vitamin E, selenium, and antioxidant status support hepatic mitochondrial function and reduce lipotoxicity, which impairs insulin signaling.
Pharmacological optimization when metabolic intervention is inadequate. Metformin reduces hepatic gluconeogenesis and improves hepatic insulin sensitivity, often raising SHBG over months. GLP-1 receptor agonists (semaglutide, tirzepatide) improve hepatic and whole-body insulin sensitivity through weight loss and direct hepatic effects. Thiazolidinediones activate PPAR-gamma and improve hepatic insulin sensitivity but carry metabolic side effects. Statins can modestly affect SHBG; the effect is complex and depends on individual baseline and statin type.
The right approach depends on your baseline SHBG, insulin level, liver status (ultrasound or FIB-4), and full metabolic context. A Loovi longevity doctor integrates SHBG with HbA1c, insulin, triglycerides, liver imaging, and body composition to map a personalized metabolic recovery plan.
SHBG alone is a starting point, not a diagnosis. Low SHBG reflects hepatic metabolic stress, but the full picture requires understanding what's driving that stress and what else has changed. Concurrent testing of fasting insulin and glucose (to calculate HOMA-IR), HbA1c, triglycerides, and HDL reveals the full metabolic syndrome phenotype. For reproductive contexts, total and bioavailable testosterone or estradiol must be measured alongside SHBG to interpret hormone bioavailability meaningfully. Liver function tests (ALT, AST, GGT) and ideally liver imaging (ultrasound to assess steatosis or FIB-4 score to assess fibrosis risk) contextualize hepatic insulin resistance. Thyroid function (TSH, free T4) rules out thyroid-driven changes in SHBG.
This is why Loovi's 120+ annual biomarkers matter. SHBG gains clinical power when paired with testosterone, estradiol, insulin, HbA1c, triglycerides, HDL, liver markers, and thyroid status. A single year's snapshot reveals metabolic trajectory; annual retesting shows whether interventions are working. The Loovi model combines this deep biomarker context with unrushed doctor consultations to build a personalized, evidence-based health plan that addresses the root causes of low SHBG, not just the number itself.
This is common and clinically important. Low SHBG means more of your testosterone is bound and less is bioavailable to tissues. If total testosterone is normal but SHBG is low, your free testosterone is below what the total number suggests — you may experience low-libido or fatigue despite “normal” total testosterone. This discordance is particularly relevant in men with insulin resistance or metabolic syndrome. Bioavailable or calculated free testosterone should be measured to clarify the picture.
No — they are related but distinct. Low SHBG reflects hepatic insulin resistance and metabolic stress. Low testosterone reflects reduced production from the testes or ovaries. You can have low SHBG with normal or even high total testosterone (more is just bound), or low SHBG with low total testosterone (compound deficiency). Testing both total testosterone and SHBG, with calculation of free testosterone, clarifies whether the issue is production or binding or both.
Yes, often substantially. Because low SHBG reflects hepatic insulin resistance, improving insulin sensitivity raises SHBG. Weight loss, exercise, reduced refined carbohydrates, and metformin all improve hepatic insulin signaling and increase SHBG over weeks to months. The speed of change depends on baseline severity and adherence to intervention. A Loovi doctor can track SHBG trajectory with annual retesting to confirm that metabolic recovery is underway.
Elevated SHBG in men can occur with hyperthyroidism, liver disease, aging, anticonvulsant use, or anabolic steroid withdrawal. While high SHBG per se indicates intact hepatic insulin sensitivity, very high SHBG reduces bioavailable testosterone and can cause low libido, erectile dysfunction, or fatigue — especially if total testosterone is low-normal. Thyroid status and reproductive hormone levels should be checked. In aging men, rising SHBG is normal and reflects declining androgens, not necessarily pathology.
SHBG is stable and does not require fasting. However, since SHBG is typically ordered alongside testosterone, insulin, and glucose, fasting is usually recommended to optimize the interpretation of the full panel. Morning sampling (before 10 a.m.) is preferred because testosterone and SHBG show modest diurnal variation.
Oral contraceptives containing estrogen substantially increase SHBG — often by 2–4 fold. This is a direct estrogenic effect on hepatic SHBG synthesis. High SHBG from oral contraceptives can reduce free testosterone and free estradiol, which may contribute to low libido in some users. SHBG testing during oral contraceptive use captures this effect; discontinuation or switching formulations may lower SHBG and increase free hormone levels.
In PCOS, low SHBG reflects both androgen excess and hepatic insulin resistance. Metformin and weight loss improve insulin sensitivity and can raise SHBG, though often incompletely because androgen excess from the ovaries persists. Anti-androgen therapy (spironolactone) or hormonal contraceptives can lower androgens and raise SHBG. The best outcomes combine metabolic intervention (weight loss, metformin) with ovarian-directed treatment as needed.
Annual testing is appropriate for metabolic monitoring and to track intervention response. If SHBG is very low or accompanied by diabetes risk markers, more frequent testing (every 6 months) during intensive metabolic intervention may be useful. Once SHBG stabilizes in the optimal range, annual retesting suffices. Loovi's annual comprehensive biomarker panel includes SHBG as standard, providing annual snapshots for tracking metabolic trajectory.
Yes. Acute exhaustive exercise can transiently suppress SHBG for 24–48 hours. For this reason, blood testing should ideally occur >48 hours after intense training. Chronic endurance or resistance training improves hepatic insulin sensitivity and raises SHBG over weeks to months, despite transient suppression from individual workouts.
Yes. Low SHBG in men is one of the strongest pre-clinical predictors of future type 2 diabetes, independent of BMI, age, or fasting glucose. Large prospective cohort studies show that men with SHBG <20 nmol/L have 3–5 fold elevated diabetes risk over 5–10 years compared to those with SHBG >30 nmol/L. This predictive power is mechanistic: SHBG reflects hepatic insulin resistance, which is the root cause of progression from normal glucose tolerance to diabetes. Paired with HbA1c and fasting insulin, SHBG offers valuable risk stratification.
